A Benefit-Risk Review of Systemic Haemostatic Agents: Part 2: In Excessive or Heavy Menstrual Bleeding

ISSN： 0114-5916

Source： Drug Safety, Vol.31, Iss.4, 2008-01, pp. : 275-282

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Benefit-Risk Review of Systemic Haemostatic Agents: Part 1: In Major Surgery

By Fraser Ian S.

Drug Safety, Vol. 31, Iss. 3, 2008-01 ,pp. : 217-230

Adis International

Access to resources Recommend Favorite

The Levonorgestrel-Releasing Intrauterine System in Heavy Menstrual Bleeding: A Benefit-Risk Review

By Kaunitz Andrew M.

Drugs, Vol. 72, Iss. 2, 2012-01 ,pp. : 193-215

Adis International

Access to resources Recommend Favorite

Pharmacological treatment of heavy menstrual bleeding varies according to the need for contraception and the presence of haemostatic impairment

By Adis International Limited

Drugs & Therapy Perspectives, Vol. 24, Iss. 10, 2008-10 ,pp. : 13-16

Adis International

Access to resources Recommend Favorite

A Benefit-Risk Assessment of Class III Antiarrhythmic Agents

By Brendorp B.

Drug Safety, Vol. 25, Iss. 12, 2002-01 ,pp. : 847-865

Adis International

Access to resources Recommend Favorite

A benefit–risk assessment of class III antiarrhythmic agents

By Elming Hanne Brendorp Bente Pehrson Steen Pedersen Ole Dyg Køber Lars Torp-Petersen Christian

Expert Opinion on Drug Safety, Vol. 3, Iss. 6, 2004-11 ,pp. : 559-577

Informa Healthcare

Access to resources Recommend Favorite